Question 1

What is Retatrutide?

Accepted Answer

Retatrutide (LY3437943) is a novel triple-hormone receptor agonist developed by Eli Lilly. It simultaneously activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It represents the most potent weight loss peptide in clinical development, achieving up to 24.

Question 2

What are the research benefits of Retatrutide?

Accepted Answer

Research on Retatrutide has investigated its potential effects in several areas, including: Unprecedented weight loss — Up to 24.2% body weight reduction at 48 weeks (NEJM Phase 2 trial, Jastreboff et al., 2023); Glycemic control — Significant HbA1c reductions in type 2 diabetes patients; Liver fat reduction — Phase 2a MASLD trial showed dramatic liver fat reduction (Nature Medicine, 2024); Improved lipid profile — Reduces triglycerides, improves cholesterol markers. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does Retatrutide work?

Accepted Answer

Triple agonism: GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation enhances insulin secretion and may improve lipid metabolism. Glucagon receptor activation increases energy expenditure, promotes hepatic fat oxidation, and may reduce liver fat. The combination of all three mechanisms creates superior weight loss and metabolic improvement compared to single or dual agonists.

Question 4

What is the FDA/legal status of Retatrutide?

Accepted Answer

Retatrutide is currently in clinical trials and is not yet FDA-approved for general use. It may only be used in the context of approved clinical trial protocols. It is not available for general consumer purchase in the United States.

Question 5

What are the known risks or side effects of Retatrutide?

Accepted Answer

Based on available research, Retatrutide has been associated with the following in study settings: Nausea (most common — dose-dependent, reduces with titration); Constipation; Decreased appetite (intended effect but can be excessive); Increased heart rate (small but measurable in trials). Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on Retatrutide?

Accepted Answer

Published research on Retatrutide can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "Retatrutide" or its aliases (LY3437943) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

Retatrutide

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.

What is the pipeline for future medications for obesity?

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer